BEVERLY HILLS, Calif., Oct. 7, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company") announced today it has entered into an agreement with Theradex Systems, Inc. ("Theradex"), a leading global contract research organization ("CRO") with extensive expertise in oncology clinical development. Through this new partnership, Theradex will lead the Company in finalizing the Investigational New Drug Application (IND #124642) with the U.S. FDA for Rich's lead drug RP-323 in patients with AML.
No one gives a _ about the price you paid for your shares or the price at which you were able to sell them.